Innoviva/$INVA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Innoviva
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
- Ticker
- $INVA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 159
- Headquarters
- Burlingame, United States
- Website
- www.inva.com
Innoviva Metrics
BasicAdvanced
$1.5B
4.93
$4.31
0.34
-
Price and volume
Market cap
$1.5B
Beta
0.34
52-week high
$25.15
52-week low
$17.77
Average daily volume
815K
Financial strength
Current ratio
16.007
Quick ratio
14.654
Long term debt to equity
0.263
Total debt to equity
0.269
Interest coverage (TTM)
9.26%
Profitability
EBITDA (TTM)
195.387
Gross margin (TTM)
72.67%
Net profit margin (TTM)
81.19%
Operating margin (TTM)
38.36%
Effective tax rate (TTM)
14.82%
Revenue per employee (TTM)
$2,770,000
Management effectiveness
Return on assets (TTM)
6.95%
Return on equity (TTM)
36.68%
Valuation
Price to earnings (TTM)
4.925
Price to revenue (TTM)
3.516
Price to book
1.25
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
8.59
Free cash flow yield (TTM)
11.64%
Free cash flow per share (TTM)
2.47
Growth
Revenue change (TTM)
18.84%
Earnings per share change (TTM)
708.30%
3-year revenue growth (CAGR)
14.85%
10-year revenue growth (CAGR)
16.81%
3-year earnings per share growth (CAGR)
17.64%
10-year earnings per share growth (CAGR)
38.60%
What the Analysts think about Innoviva
Analyst ratings (Buy, Hold, Sell) for Innoviva stock.
Analyst projections of the future price of Innoviva stock.
Bulls say / Bears say
Innoviva Specialty Therapeutics is growing quickly: second-quarter net product sales rose 46% year on year, and management said it remains on track for at least $150 million in US sales in 2026. That gives the company a growing commercial business alongside its royalties. (Innoviva)
A Dr. Reddy’s deal gives XACDURO a route into South and Central America, the Caribbean, Russia and CIS markets. Innoviva is eligible for upfront and milestone payments and royalties, adding potential growth beyond US sales. (Innoviva Specialty Therapeutics)
The company had $570.4 million in cash at the end of June and had repurchased $56.4 million of shares under its buyback programme since its launch. This provides financial flexibility and a direct way to return capital to shareholders. (Innoviva)
GSK royalty revenue is declining: net royalties fell to $56.3 million in the second quarter from $63.9 million a year earlier, and first-half royalties also fell year on year. Continued erosion would weigh on a key source of revenue. (SEC)
Investment values add substantial earnings volatility. A $161 million unfavourable change in investment fair values, mainly linked to Armata’s lower share price, contributed to an $83.4 million net loss in the second quarter. (Innoviva)
Revenue growth has not yet lifted operating profit: first-half revenue rose to $217.6 million from $188.9 million, while operating income edged down to $89.0 million from $90.2 million. Higher selling, general and administrative costs are one reason growth may not flow through to profit. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
Innoviva Financial Performance
Revenues and expenses
Innoviva Earnings Performance
Company profitability
Upcoming events
No upcoming events
Innoviva News
AllArticlesVideos
Funds containing Innoviva
AllUSDEURGBP
Fund name | Fund size | $INVA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.10% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.10% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.09% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.